HEADER APOPTOSIS 12-AUG-09 3INQ TITLE CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH W1191542 COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 1-209; COMPND 5 SYNONYM: BCL2-L-1, APOPTOSIS REGULATOR BCL-X; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL-X; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PGEX-6P3 KEYWDS APOPTOSIS, ALTERNATIVE SPLICING, MEMBRANE, MITOCHONDRION, NUCLEUS, KEYWDS 2 TRANSMEMBRANE EXPDTA X-RAY DIFFRACTION AUTHOR W.D.FAIRLIE,B.J.SMITH,P.M.COLMAN,P.E.CZABOTAR,E.F.LEE REVDAT 4 01-NOV-23 3INQ 1 REMARK SEQADV REVDAT 3 23-AUG-17 3INQ 1 JRNL REVDAT 2 16-AUG-17 3INQ 1 SOURCE REMARK REVDAT 1 01-SEP-09 3INQ 0 JRNL AUTH E.F.LEE,P.E.CZABOTAR,H.YANG,B.E.SLEEBS,G.LESSENE,P.M.COLMAN, JRNL AUTH 2 B.J.SMITH,W.D.FAIRLIE JRNL TITL CONFORMATIONAL CHANGES IN BCL-2 PRO-SURVIVAL PROTEINS JRNL TITL 2 DETERMINE THEIR CAPACITY TO BIND LIGANDS JRNL REF J. BIOL. CHEM. V. 284 30508 2009 JRNL REFN ESSN 1083-351X JRNL PMID 19726685 JRNL DOI 10.1074/JBC.M109.040725 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 31.63 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 21183 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.197 REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.250 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.150 REMARK 3 FREE R VALUE TEST SET COUNT : 1090 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 31.6344 - 4.0004 1.00 2671 129 0.1827 0.2095 REMARK 3 2 4.0004 - 3.1762 1.00 2554 130 0.1691 0.2287 REMARK 3 3 3.1762 - 2.7750 1.00 2505 148 0.1916 0.2663 REMARK 3 4 2.7750 - 2.5214 1.00 2475 146 0.2061 0.2553 REMARK 3 5 2.5214 - 2.3407 1.00 2492 131 0.1975 0.2953 REMARK 3 6 2.3407 - 2.2028 1.00 2472 142 0.2013 0.2466 REMARK 3 7 2.2028 - 2.0925 1.00 2474 138 0.2441 0.2857 REMARK 3 8 2.0925 - 2.0014 0.99 2450 126 0.2846 0.3635 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.36 REMARK 3 B_SOL : 62.08 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.580 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : NULL REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.013 2480 REMARK 3 ANGLE : 1.390 3336 REMARK 3 CHIRALITY : 0.095 336 REMARK 3 PLANARITY : 0.006 421 REMARK 3 DIHEDRAL : 19.098 871 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3INQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 20-AUG-09. REMARK 100 THE DEPOSITION ID IS D_1000054639. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-MAY-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI FILTER REMARK 200 OPTICS : AXCO CAPILLARY OPTIC REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV++ REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 21237 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 6.800 REMARK 200 R MERGE (I) : 0.08600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 31.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 6.30 REMARK 200 R MERGE FOR SHELL (I) : 0.86700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 3FDL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.11 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.12 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2M CALCIUM ACETATE, 10%(W/V) REMARK 280 PEG8000, 0.1M IMIDAZOLE, PH 8.0, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 298.0K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 31.29400 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 35.70050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 34.10700 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 35.70050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 31.29400 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 34.10700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4250 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 14080 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -29.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 PRO A -3 REMARK 465 LEU A -2 REMARK 465 GLY A -1 REMARK 465 SER A 0 REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 ASN A 197 REMARK 465 ASN A 198 REMARK 465 ALA A 199 REMARK 465 ALA A 200 REMARK 465 ALA A 201 REMARK 465 GLU A 202 REMARK 465 SER A 203 REMARK 465 ARG A 204 REMARK 465 LYS A 205 REMARK 465 GLY A 206 REMARK 465 GLN A 207 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 465 GLY B -4 REMARK 465 PRO B -3 REMARK 465 LEU B -2 REMARK 465 GLY B -1 REMARK 465 SER B 0 REMARK 465 ASN B 197 REMARK 465 ASN B 198 REMARK 465 ALA B 199 REMARK 465 ALA B 200 REMARK 465 ALA B 201 REMARK 465 GLU B 202 REMARK 465 SER B 203 REMARK 465 ARG B 204 REMARK 465 LYS B 205 REMARK 465 GLY B 206 REMARK 465 GLN B 207 REMARK 465 GLU B 208 REMARK 465 ARG B 209 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 ARG A 102 CZ REMARK 480 ARG A 132 CG CZ REMARK 480 ARG A 139 NH2 REMARK 480 GLN A 183 CD REMARK 480 GLN B 3 CD REMARK 480 ARG B 6 CZ REMARK 480 ARG B 132 CZ REMARK 480 GLN B 183 CD REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 132 -18.79 -45.88 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE X0J A 210 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 211 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 212 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 213 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 214 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 215 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 216 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 217 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 218 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO A 219 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE X0J B 210 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO B 212 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EDO B 213 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2YXJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH ABT-737 REMARK 900 RELATED ID: 3FDL RELATED DB: PDB REMARK 900 BIM BH3 PEPTIDE IN COMPLEX WITH BCL-XL REMARK 900 RELATED ID: 2P1L RELATED DB: PDB REMARK 900 STRUCTURE OF THE BCL-XL:BECLIN 1 COMPLEX REMARK 900 RELATED ID: 3IO8 RELATED DB: PDB REMARK 900 RELATED ID: 3IO9 RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 BCL-XL WITH AMINO ACIDS 27 TO 82 DELETED AND A C-TERMINAL REMARK 999 TRUNCATION OF THE LAST 24 RESIDUES REMARK 999 THE NUMBERING OF THE PROTEIN IS NON-SEQUENTIAL. DBREF 3INQ A 1 26 UNP Q07817 B2CL1_HUMAN 1 26 DBREF 3INQ A 83 209 UNP Q07817 B2CL1_HUMAN 83 209 DBREF 3INQ B 1 26 UNP Q07817 B2CL1_HUMAN 1 26 DBREF 3INQ B 83 209 UNP Q07817 B2CL1_HUMAN 83 209 SEQADV 3INQ GLY A -4 UNP Q07817 EXPRESSION TAG SEQADV 3INQ PRO A -3 UNP Q07817 EXPRESSION TAG SEQADV 3INQ LEU A -2 UNP Q07817 EXPRESSION TAG SEQADV 3INQ GLY A -1 UNP Q07817 EXPRESSION TAG SEQADV 3INQ SER A 0 UNP Q07817 EXPRESSION TAG SEQADV 3INQ GLY B -4 UNP Q07817 EXPRESSION TAG SEQADV 3INQ PRO B -3 UNP Q07817 EXPRESSION TAG SEQADV 3INQ LEU B -2 UNP Q07817 EXPRESSION TAG SEQADV 3INQ GLY B -1 UNP Q07817 EXPRESSION TAG SEQADV 3INQ SER B 0 UNP Q07817 EXPRESSION TAG SEQRES 1 A 158 GLY PRO LEU GLY SER MET SER GLN SER ASN ARG GLU LEU SEQRES 2 A 158 VAL VAL ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY SEQRES 3 A 158 TYR SER TRP SER GLN MET ALA ALA VAL LYS GLN ALA LEU SEQRES 4 A 158 ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG ARG SEQRES 5 A 158 ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR PRO SEQRES 6 A 158 GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN GLU SEQRES 7 A 158 LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL ALA SEQRES 8 A 158 PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER VAL SEQRES 9 A 158 ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA ALA SEQRES 10 A 158 TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO TRP SEQRES 11 A 158 ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU LEU SEQRES 12 A 158 TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY GLN SEQRES 13 A 158 GLU ARG SEQRES 1 B 158 GLY PRO LEU GLY SER MET SER GLN SER ASN ARG GLU LEU SEQRES 2 B 158 VAL VAL ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY SEQRES 3 B 158 TYR SER TRP SER GLN MET ALA ALA VAL LYS GLN ALA LEU SEQRES 4 B 158 ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG ARG SEQRES 5 B 158 ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR PRO SEQRES 6 B 158 GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN GLU SEQRES 7 B 158 LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL ALA SEQRES 8 B 158 PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER VAL SEQRES 9 B 158 ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA ALA SEQRES 10 B 158 TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO TRP SEQRES 11 B 158 ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU LEU SEQRES 12 B 158 TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY GLN SEQRES 13 B 158 GLU ARG HET X0J A 210 55 HET EDO A 211 4 HET EDO A 212 4 HET EDO A 213 4 HET EDO A 214 4 HET EDO A 215 4 HET EDO A 216 4 HET EDO A 217 4 HET EDO A 218 4 HET EDO A 219 4 HET X0J B 210 55 HET CL B 211 1 HET EDO B 212 4 HET EDO B 213 4 HETNAM X0J 4-[4-(BIPHENYL-3-YLMETHYL)PIPERAZIN-1-YL]-N-{[4-({(1R)- HETNAM 2 X0J 3-(DIMETHYLAMINO)-1-[(PHENYLSULFANYL) HETNAM 3 X0J METHYL]PROPYL}AMINO)-3-NITROPHENYL]SULFONYL}BENZAMIDE HETNAM EDO 1,2-ETHANEDIOL HETNAM CL CHLORIDE ION HETSYN EDO ETHYLENE GLYCOL FORMUL 3 X0J 2(C42 H46 N6 O5 S2) FORMUL 4 EDO 11(C2 H6 O2) FORMUL 14 CL CL 1- FORMUL 17 HOH *136(H2 O) HELIX 1 1 GLN A 3 GLN A 19 1 17 HELIX 2 2 SER A 25 TYR A 101 1 21 HELIX 3 3 TYR A 101 SER A 110 1 10 HELIX 4 4 ALA A 119 PHE A 131 1 13 HELIX 5 5 ASN A 136 LYS A 157 1 22 HELIX 6 6 MET A 159 VAL A 161 5 3 HELIX 7 7 LEU A 162 ASN A 185 1 24 HELIX 8 8 GLY A 186 GLY A 196 1 11 HELIX 9 9 MET B 1 LYS B 20 1 20 HELIX 10 10 SER B 25 TYR B 101 1 21 HELIX 11 11 TYR B 101 GLN B 111 1 11 HELIX 12 12 ALA B 119 PHE B 131 1 13 HELIX 13 13 ASN B 136 LYS B 157 1 22 HELIX 14 14 MET B 159 LEU B 178 1 20 HELIX 15 15 LEU B 178 ASN B 185 1 8 HELIX 16 16 GLY B 186 GLY B 196 1 11 SITE 1 AC1 15 ALA A 93 GLU A 96 PHE A 97 TYR A 101 SITE 2 AC1 15 LEU A 108 GLU A 129 ARG A 132 ASN A 136 SITE 3 AC1 15 TRP A 137 GLY A 138 VAL A 141 PHE A 191 SITE 4 AC1 15 TYR A 195 EDO A 217 ARG B 102 SITE 1 AC2 6 VAL A 192 GLU A 193 LEU A 194 HOH A 310 SITE 2 AC2 6 TYR B 101 X0J B 210 SITE 1 AC3 3 SER A 14 MET A 83 LYS A 87 SITE 1 AC4 5 GLN A 88 ARG A 91 EDO A 214 ASP B 11 SITE 2 AC4 5 ARG B 91 SITE 1 AC5 5 ASP A 11 ARG A 91 EDO A 213 GLN B 88 SITE 2 AC5 5 ARG B 91 SITE 1 AC6 3 GLN A 160 HOH A 237 TRP B 24 SITE 1 AC7 5 LYS A 16 GLN A 19 LYS A 20 HOH A 231 SITE 2 AC7 5 GLU B 98 SITE 1 AC8 3 ASN A 136 ARG A 139 X0J A 210 SITE 1 AC9 5 ARG A 100 TYR A 101 ARG A 102 ARG A 103 SITE 2 AC9 5 ALA A 104 SITE 1 BC1 2 HOH A 71 ARG A 165 SITE 1 BC2 13 GLU A 193 EDO A 211 GLU B 96 PHE B 97 SITE 2 BC2 13 TYR B 101 LEU B 108 ASN B 136 TRP B 137 SITE 3 BC2 13 GLY B 138 VAL B 141 PHE B 146 PHE B 191 SITE 4 BC2 13 TYR B 195 SITE 1 BC3 2 GLY B 21 EDO B 213 SITE 1 BC4 2 GLY B 196 EDO B 212 CRYST1 62.588 68.214 71.401 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015978 0.000000 0.000000 0.00000 SCALE2 0.000000 0.014660 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014005 0.00000